Astragaloside IV Alleviates Heart Failure by Modulating Nrf-2
Heart failure (HF) impacts 1–2% of adults worldwide, making it one of the most prevalent and challenging cardiovascular conditions to treat effectively. While existing therapies help some patients, many only work in preclinical settings, leaving millions searching for more reliable options. Now, research from scientists at Shandong University of Traditional Chinese Medicine highlights a promising natural compound—astragaloside IV (AS-IV)—that may offer new hope by targeting a critical cellular pathway involved in heart health.
AS-IV is a key active ingredient in Astragalus membranaceus Bunge, a herb used for centuries in traditional Chinese medicine to support cardiovascular function. For this study, led by Wenxiao Feng, Jie Yang, Yan Li, Haiyan Sun, Juan Zhang, and Yitao Xue, the team set out to test whether AS-IV could protect against HF caused by doxorubicin (Dox), a chemotherapy drug known to damage the heart.
How the Study Worked
The researchers first induced HF in Wistar rats by injecting Dox twice weekly for six weeks. After one week of Dox treatment, half the rats received daily 1.0 mg/kg AS-IV injections, while the other half got saline (a control). At nine weeks, they used echocardiography to measure heart function—and the results were clear: AS-IV-treated rats had significantly higher left ventricular ejection fraction (EF), a key marker of how well the heart pumps blood, compared to the control group.
Further tests revealed more benefits: Wheat germ agglutinin (WGA) staining showed AS-IV reduced the enlarged cardiomyocytes (heart muscle cells) caused by Dox. TUNEL assays—used to detect cell death—found fewer apoptotic (dying) cells in AS-IV-treated hearts. The team also looked at mitochondrial health, a critical factor in HF: Dox disrupts proteins that control mitochondrial fusion (mitofusin 1/2) and fission (DRP1), leading to dysfunction. AS-IV reversed these changes, balancing DRP1 and mitofusin levels to keep mitochondria healthy.
Most importantly, AS-IV reactivated Nrf-2—a protein that acts as a “cellular stress fighter”—and its downstream target HO-1. Both are impaired in HF, so restoring their function helps cells resist damage.
Lab Tests Confirm AS-IV’s Effects
To validate their findings, the team tested AS-IV on H9C2 cardiomyoblast cells (a lab model of heart cells) exposed to Dox. Again, AS-IV worked: it reduced cell apoptosis (programmed cell death) and restored mitochondrial membrane potential (a sign of healthy mitochondria) in a dose-dependent way. It also balanced DRP1/mitofusin levels and reactivated Nrf-2/HO-1—matching the results from the rat experiments.
What This Means for Patients
The study, published in the Chinese Medical Journal in 2022, suggests AS-IV’s cardioprotective effects come partly from modulating the Nrf-2 pathway. This is a big step forward because Nrf-2 is a master regulator of cellular defense, and its dysfunction is linked to HF progression. For cancer patients undergoing Dox therapy, AS-IV could also help ease cardiotoxicity—a common, dangerous side effect of the drug.
While more research (including human clinical trials) is needed to confirm AS-IV’s safety and efficacy, these findings add to growing evidence that traditional Chinese medicine compounds have scientific merit. They also provide molecular proof for why Astragalus membranaceus has been trusted for heart health for millennia.
The study “Astragaloside IV alleviates heart failure by modulating Nrf-2” was published in the Chinese Medical Journal (2022) by Wenxiao Feng, Jie Yang, Yan Li, Haiyan Sun, Juan Zhang, and Yitao Xue from the First Clinical Medical College and Affiliated Hospital of Shandong University of Traditional Chinese Medicine. doi.org/10.1097/CM9.0000000000001828
Was this helpful?
0 / 0